| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9789064 | INVAGEN PHARMS | Method for delivering a peptide to a subject at a modulated rate via microcapsules of lactic-co-glycolic copolymer containing said peptide |
Dec, 2020
(3 years ago) | |
Leuprolide Acetate For Depot Suspension is owned by Invagen Pharms.
Leuprolide Acetate For Depot Suspension contains Leuprolide Acetate.
Leuprolide Acetate For Depot Suspension has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Leuprolide Acetate For Depot Suspension are:
- US9789064
Leuprolide Acetate For Depot Suspension was authorised for market use on 28 August, 2018.
Leuprolide Acetate For Depot Suspension is available in for suspension;intramuscular dosage forms.
The generics of Leuprolide Acetate For Depot Suspension are possible to be released after 15 December, 2020.
Drugs and Companies using LEUPROLIDE ACETATE ingredient
Market Authorisation Date: 28 August, 2018
Treatment: NA
Dosage: FOR SUSPENSION;INTRAMUSCULAR
LEUPROLIDE ACETATE FOR DEPOT SUSPENSION family patents
